CION Ameerpet
Kidney Cancer · Treatment & Modalities
SBRT for kidney cancer — focused radiation, and where it actually fits
If you have been told that kidney cancer “does not respond to radiation”, that was true of the radiotherapy of a generation ago and is no longer the whole picture. SBRT — stereotactic body radiation therapy — delivers a much higher dose to a tightly drawn target over a short course, and it has given radiation a real role in kidney cancer: treating a tumour in someone who cannot have an operation, and treating a limited number of secondary sites. This page explains what SBRT is, where it fits, and what a course involves. Radiation is delivered in-house at CION; kidney surgery, ablation and PET-CT are coordinated with specialist partner centres.
- It is precision, not stronger rays — the target is mapped in three dimensions and tracked as you breathe, so a high dose can be concentrated inside it while the kidney, bowel and spinal cord alongside are spared.
- It has not replaced surgery — where an operation is safe it remains the standard for a tumour confined to the kidney. SBRT matters most where an operation is not safe, or would cost more kidney function than you can spare.
- Its other main use is limited spread — where the disease sits in a small, countable number of places, focused radiation can treat each of them alongside immunotherapy or targeted therapy, and can settle bone pain quickly.
- How CION works — simulation, planning, delivery, kidney-function monitoring, tumour-board review and follow-up are in-house; nephrectomy, ablation and PET-CT are coordinated with specialist urology, uro-oncology and interventional-radiology partners and may be billed at the partner centre.
17+
Cancer Specialists
on Panel
on Panel
35+
Centres across
Telangana & AP
Telangana & AP
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start here
What SBRT is — and why radiation is back in the kidney cancer conversation
SBRT is stereotactic body radiation therapy: a small number of very precisely aimed, high-dose treatments. Ordinary radiotherapy spreads a modest dose over several weeks and treats a fairly generous area around the target. SBRT inverts that. The tumour is outlined on a dedicated planning scan, the way it shifts with every breath is measured, and a much larger dose per session is concentrated inside a tightly drawn volume that the dose then falls away from sharply at its edge. Nothing is cut. You lie still on a couch, the machine images you and moves around you, and you go home the same day.
The reputation kidney cancer has for shrugging off radiation was earned honestly — by a different treatment. Conventional fractionated radiotherapy, given in small daily doses, did not control renal cell carcinoma reliably, which is why radiation has for decades been described in kidney cancer as something used to ease symptoms rather than to treat the tumour, and why you may have read that chemotherapy and radiation “do not work” here. Delivering a far higher dose in each session changes the arithmetic, and renal cell carcinoma appears considerably more sensitive to being treated that way. That is a change in technique, not a change in the biology of the disease, and it has not displaced anything: where an operation can be done safely, surgery remains the standard for a tumour confined to the kidney.
So the honest framing is narrow, and worth stating plainly. Focused radiation earns its place in two situations. The first is a tumour still inside the kidney in someone for whom an operation is the larger risk — because of age, heart or lung disease, already reduced kidney function or a single working kidney — and where ablation is either unsuitable or unavailable. NCCN guidance recognises stereotactic radiation among the options for selected people with a kidney primary who are not candidates for surgery or ablation. The second is limited spread, where the disease sits in a small, countable number of sites and each can be treated in turn; that situation is covered in detail on our page about oligometastatic kidney cancer (limited spread). Beyond those two, radiation is still used the way it always was: to control a specific problem, such as pain from a bone deposit.
Where CION sits in this. Radiation is one of the treatments we deliver ourselves. The planning scan and simulation, the contouring and dose planning, the physics checks, image-guided delivery, kidney-function monitoring through the course and the follow-up afterwards are all in-house and led by radiation and medical oncology together, with every kidney case read at a uro-oncology tumour board before a recommendation is made. The alternatives that get weighed against it are not: partial and radical nephrectomy, robotic surgery, tumour ablation and PET-CT staging are coordinated with specialist urology, uro-oncology and interventional-radiology partners and may be billed at the partner centre. What sits where across the whole pathway is set out on our kidney cancer treatment in Hyderabad page, and the condition itself — types, stages, symptoms and risk factors — on our complete kidney cancer guide.
Four questions turn “they mentioned radiation” into a decision you can actually take part in:
- Is SBRT being offered because surgery is unsafe, or because it is genuinely the better option here? Those are different conversations, and you are entitled to know which one you are in.
- What was weighed against it? For a tumour inside the kidney that usually means kidney-sparing surgery, ablation, and in some cases monitoring — ask why each was set aside.
- Is the diagnosis settled? Radiation removes no tissue, so if there has been no biopsy, ask whether one should be done before treatment rather than after.
- What will follow-up look like? Treated kidney tumours often shrink slowly and stay visible on scans for a long time, so agree in advance how response will be judged.
If radiation has been mentioned and nothing else was explained, that is worth an hour with an oncologist. Book a free consultation and bring the scans and reports you already have.
A treated tumour that does not shrink is not the same as a treatment that failed
After focused radiation, a kidney tumour is usually still visible on the scan — often for a long time, and often at close to its original size. Radiation works by damaging the cells so they cannot keep dividing, not by dissolving the mass, so the imaging change lags a long way behind the biological one. This is one of the real differences between radiation and an operation, and it is why response is judged on a pattern across several scans read by people used to reading them, rather than on the first scan after treatment.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Radiation should be chosen, not defaulted to
Every kidney case at CION is read at a uro-oncology tumour board before anything is recommended, so radiation is weighed against the surgical and ablative options rather than picked in isolation. Free first consultation, no commitment to proceed.
Where it fits
Situations where focused radiation is considered — and where it is not the first answer
Read this to follow the conversation you are about to have, not to decide your own plan. These situations overlap, and only a team that has seen your scans, your kidney function and you can put them in order.
| The situation | Where focused radiation fits | What is usually weighed alongside it |
|---|---|---|
| A tumour inside the kidney, but an operation is unsafe | The core use. NCCN guidance recognises stereotactic radiation among the options for selected people with a kidney primary who are not candidates for surgery or ablation — age, heart or lung disease, reduced kidney function or a single working kidney being the usual reasons. | Tumour ablation, and in some cases continued monitoring. Both are weighed first, and ablation is coordinated with interventional-radiology partners. |
| A small renal mass in someone fit for an operation | Rarely the first choice. For a small tumour — the T1a category is 4 cm or less — surgery and ablation have the longer track record, and radiation is generally held in reserve. | Kidney-sparing surgery, ablation, or active surveillance for small kidney tumours where watching is appropriate. |
| The tumour sits awkwardly for ablation | A useful alternative. A tumour close to the collecting system, or one a needle cannot safely reach, can sometimes be treated with radiation when it cannot be ablated. | The route into the tumour is an interventional-radiology judgement, made with the surgical team before radiation is chosen. |
| Spread limited to a small number of sites | The other main use. Each site — lung, bone, lymph node, adrenal — can be treated in turn to control disease where it sits and to delay a change of systemic treatment. | Immunotherapy or targeted therapy, which continue alongside; sequencing is a tumour-board decision. See oligometastatic kidney cancer (limited spread). |
| A painful bone deposit, or one at risk of fracture | The long-standing use of radiation in kidney cancer, and still one of the most valuable. It is aimed at the symptom and often settles pain without adding to the drug burden. | Orthopaedic input where a bone is structurally at risk, bone-protective treatment, and pain management. |
| Spread to the brain | Stereotactic radiation is the same principle applied inside the skull, treating a small number of deposits precisely rather than irradiating the whole brain. | Neurosurgical opinion where a deposit is large or causing pressure, and how it fits with systemic treatment. |
| Disease that is widespread | Not a substitute for systemic treatment. Radiation is then used for a specific problem — a painful site, bleeding, or a deposit pressing on something — rather than for the disease as a whole. | Immunotherapy and targeted therapy lead the plan; radiation supports it. |
| The diagnosis is not settled yet | Too early. Radiation removes no tissue, so it produces no specimen; treating before the mass is characterised can leave the diagnosis permanently unresolved. | Dedicated renal-mass imaging and, where it would change the plan, a biopsy — both in-house at CION. |
How focused radiation sits within the full set of kidney cancer treatments, and which parts are delivered in-house versus coordinated with partners, is set out on our kidney cancer treatment in Hyderabad page.
Honest trade-offs
What SBRT offers, and what it asks of you
Focused radiation is offered where it is the option with the least total harm for a particular person — not because it is uniformly better or uniformly gentler. Both sides are worth knowing before you agree to it.
The case for it
What SBRT offers
Treatment without an operation. For people whose bigger risk is the anaesthetic and the recovery rather than the tumour, that is the whole point.
- No incision, no anaesthetic and no hospital admission for the treatment itself.
- No kidney tissue is removed, and dose limits for both kidneys are built into the plan from the start.
- A short course rather than weeks of daily attendance, and most people carry on with normal activity through it.
- It can reach targets a needle cannot, and can be aimed at more than one site when spread is limited.
- It is delivered in-house at CION by radiation oncology, planned at a tumour board with medical oncology in the room.
The honest costs
What SBRT asks
Accepting a slower, less definite answer than an operation gives. Radiation treats the tumour where it lies; it does not take it out and put it under a microscope.
- No tissue is removed, so there is no surgical specimen — if the diagnosis is not settled, a biopsy has to be planned separately.
- Response is slow on imaging and the mass often stays visible, which can be unsettling and needs experienced interpretation.
- Not every tumour suits it — size, and how close the target sits to bowel or stomach, can rule it out.
- Tiredness is common, with nausea when the treated area is near the stomach or bowel, and some loss of function on the treated side is possible.
- For a tumour that could safely be operated on, surgery still has the longer track record, so choosing radiation instead deserves an explicit conversation.
What choosing radiation does not close off. Being treated with SBRT does not remove surgery, ablation or systemic treatment from the plan later — those decisions are revisited at the tumour board as the situation changes. Systemic treatment for kidney cancer is described by class on this site, immunotherapy and targeted therapy rather than chemotherapy; if you are looking for information about a specific drug you have been prescribed, that belongs on our kidney cancer treatment page and, more usefully still, in a conversation with the oncologist who prescribed it.
The kidney moves every time you breathe — and the plan has to know how much
A kidney tumour is not a fixed target. It travels with the diaphragm through every breath, which is why a plain planning scan is not enough for SBRT. The planning session measures that movement, and the course is then delivered either with your breathing held in a repeatable position, or with a margin built to cover the path the tumour actually takes. It is the least visible part of the preparation and one of the most important, because a dose this concentrated only spares what surrounds it if the target is genuinely where the plan says it is.
From scan to schedule
What an SBRT course actually involves
The number of sessions, the dose and the intervals are set by your radiation oncologist from the size of the target, where it sits and what healthy tissue surrounds it. What follows is the shape of the process, not a timetable.
The diagnosis and the staging are settled first
A dedicated contrast CT of the kidneys, or an MRI where contrast dye is a problem, establishes the size of the tumour, where it sits and what is next to it. Where the extent of disease decides whether radiation is being used to treat or to control, staging is completed before planning — including PET-CT where it is needed, which is coordinated with specialist partner centres. Imaging review and biopsy are done in-house at CION.
The tumour board decides that radiation is the right tool
Medical and radiation oncologists, with radiology and surgical input, weigh focused radiation against the alternatives for this particular tumour and this particular person — kidney-sparing or radical surgery and ablation, both coordinated with specialist urology, uro-oncology and interventional-radiology partners. A team reading, not one doctor’s impression, and it is how every kidney case at CION is handled.
A planning session maps you in the treatment position
Also called simulation. You are set up exactly as you will lie for every session, usually with a support or immobilisation device, and a planning CT is taken in that position. Small reference marks may be placed on the skin. Nothing is treated on this visit — its whole purpose is to make the position repeatable to within a very small margin.
Your breathing is measured and accounted for
The kidney moves with the diaphragm, so the plan has to cover where the tumour travels, not just where it sits at one instant. That is handled either by treating with your breath held in a repeatable position, or by building the measured range of movement into the target volume. Which approach is used depends on the tumour, and on what you can comfortably manage.
The target is outlined and the dose is shaped around what must be spared
The radiation oncologist contours the tumour and every nearby structure that has to be protected — the treated kidney, the opposite kidney, bowel, stomach, liver, spinal cord. Limits are set for each, and medical physics checks the plan against them before it is accepted. Protecting kidney function is a constraint written into the plan, not an outcome hoped for afterwards.
Delivery is short, painless and image-guided
You are imaged on the couch before each session, and often during it, so the position is confirmed against the plan rather than assumed. The treatment itself is felt as nothing at all; each session takes longer to set up than to deliver, and most people go home afterwards and carry on. Tiredness builds gradually, and nausea can occur when the treated area is near the stomach or bowel.
Follow-up watches the pattern, not the first scan
Treated kidney tumours shrink slowly and often stay visible, so response is judged across a sequence of scans rather than from the first one after treatment. Kidney-function bloods and blood-pressure checks continue alongside, and anything that changes goes back to the tumour board. Follow-up runs in-house at CION for as long as the plan does.
One thing worth raising yourself. If radiation is being proposed for a mass that has never been biopsied, ask directly whether a biopsy should come first. Radiation removes no tissue and therefore produces no specimen, so a diagnosis not made before treatment can be difficult to make afterwards — and it is the diagnosis, not the size alone, that decides what happens next if the tumour ever behaves differently.
Take the first step
Ask what else was on the table — before the course is booked
Every case at CION goes to a tumour board, not one doctor’s opinion. Bring the scans you have and we will go through them with you in 45 unhurried minutes.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Questions people ask about focused radiation for kidney cancer
Is SBRT an option if I can't have surgery?
Often, yes, and it is one of the main reasons stereotactic radiation is used in kidney cancer at all. Where a tumour is still confined to the kidney but an operation is not safe, because of age, heart or lung disease, already reduced kidney function or a single working kidney, focused radiation offers a way of treating it without an anaesthetic and without removing kidney tissue. NCCN guidance recognises stereotactic radiation among the options for selected people with a kidney primary who are not candidates for surgery or ablation. Whether it fits you depends on where the tumour sits, how large it is and what healthy tissue is next to it, which is what the tumour board weighs. Radiation is delivered in-house at CION; surgery and ablation are coordinated with specialist partner centres.
What is SBRT, and how is it different from ordinary radiotherapy?
SBRT stands for stereotactic body radiation therapy. Conventional radiotherapy gives a modest dose each day over several weeks to a fairly generous area. SBRT does close to the opposite. The target is mapped in three dimensions, the way it moves as you breathe is measured and accounted for, and a much higher dose is delivered to a tightly drawn volume over a short course of visits. The dose falls away sharply at the edge of that volume, which is what allows the kidney, bowel, liver and spinal cord nearby to be spared. Nothing is cut and nothing is removed. You lie still on a couch and the machine moves around you. The precision, rather than the radiation itself, is what makes it a different treatment.
Isn't kidney cancer supposed to be resistant to radiation?
That reputation was earned in the era of conventional fractionated radiotherapy, where the modest daily doses used did not control renal cell carcinoma reliably. It is why radiation has long been described in kidney cancer as a way of easing symptoms rather than treating the tumour itself, and why chemotherapy and radiation are both said not to work well here. Stereotactic radiation changes that picture by delivering a far higher dose in each session, a level renal cell carcinoma appears considerably more sensitive to. It has not displaced surgery, which remains the standard for a tumour that can safely be operated on. What it has done is make radiation a real option for tumours that cannot be, and for treating a limited number of secondary sites.
How many sessions will I need, and does SBRT hurt?
An SBRT course is short, a handful of high-dose sessions rather than daily treatment stretching over weeks, but the exact number is set by your radiation oncologist from the size of the target, where it sits and what healthy tissue surrounds it. It is not a number to take off a web page. The treatment itself is painless. You lie still in the same position each time, the machine images you before and often during delivery, and each session takes longer to set up than to deliver. Most people go home the same day and carry on with normal activity. Tiredness is the commonest after-effect, along with some nausea when the treated area sits close to the stomach or bowel.
Will SBRT damage my remaining kidney function?
Protecting kidney function is written into the plan rather than hoped for afterwards. Before a plan is accepted, limits are set for how much dose the treated kidney, the opposite kidney and the surrounding organs may receive, and the plan is approved only if it stays inside them. This matters most for the people most often offered SBRT in the first place, those with one working kidney or with function that is already reduced. Kidney function bloods are checked beforehand and followed afterwards. Some loss of function on the treated side is possible, and that has to be weighed against the alternative being considered, which is usually an operation that removes kidney tissue outright.
Can SBRT be used if the cancer has spread to a few places?
Yes, and in kidney cancer this has become one of its commonest uses. Where spread is limited to a small, countable number of sites, a pattern described as oligometastatic, treating each of those sites with focused radiation can control the disease where it sits, ease symptoms such as bone pain, and sometimes postpone the point at which systemic treatment has to be changed. It is used alongside immunotherapy or targeted therapy rather than instead of them, and the order of events is a tumour-board decision. It also depends on the staging being reliable, which is where dedicated imaging, including PET-CT coordinated with partner centres, comes in. Our page on oligometastatic kidney cancer covers how those cases are planned.
This page is general health information about stereotactic body radiation therapy in kidney cancer. It is not a diagnosis and it cannot replace a specialist review of your own scans, blood results and medical history. Whether focused radiation is appropriate, and what dose and schedule it should follow, depends on findings that only a team who has examined your imaging and you can weigh. Radiation, diagnosis and follow-up are delivered in-house at CION; kidney surgery, tumour ablation and PET-CT are coordinated with specialist urology, uro-oncology and interventional-radiology partners and may be billed at the partner centre. If radiation has been mentioned and you are not sure what was weighed against it, ask us before the course is booked.